Treating arthritis by immunomodulation: is there a role for regulatory T cells?

The discovery of regulatory T cells almost 15 years ago initiated a new and exciting research area. The growing evidence for a critical role of these cells in controlling autoimmune responses has raised expectations for therapeutic application of regulatory T cells in patients with autoimmune arthritis. Here, we review recent studies investigating the presence, phenotype and function of these cells in patients with RA and juvenile idiopathic arthritis (JIA) and consider their therapeutic potential. Both direct and indirect methods to target these cells will be discussed. Arguably, a therapeutic approach that combines multiple regulatory T-cell-enhancing strategies could be most successful for clinical application.

[1]  E. Kalkhoven,et al.  Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. , 2010, Blood.

[2]  H. Sai,et al.  Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. , 2010, Gastroenterology.

[3]  Wayne W. Hancock,et al.  Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells , 2009, Nature Reviews Drug Discovery.

[4]  E. Matteson,et al.  Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. , 2009, Arthritis and rheumatism.

[5]  G. Lal,et al.  Epigenetic mechanisms of regulation of Foxp3 expression. , 2009, Blood.

[6]  Zhanju Liu,et al.  All‐trans retinoic acid down‐regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis , 2009, Journal of leukocyte biology.

[7]  Yuan Shen,et al.  Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. , 2009, Experimental and molecular pathology.

[8]  T. Huizinga,et al.  De Novo Generation and Enhanced Suppression of Human CD4+CD25+ Regulatory T Cells by Retinoic Acid1 , 2009, The Journal of Immunology.

[9]  J. Bluestone,et al.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.

[10]  L. Wedderburn,et al.  Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. , 2009, Rheumatology.

[11]  G. Illei,et al.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. , 2009, Blood.

[12]  M. Neurath,et al.  Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. , 2009, Gastroenterology.

[13]  B. Malissen,et al.  Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity , 2009, Proceedings of the National Academy of Sciences.

[14]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[15]  M. Ehrenstein,et al.  Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis , 2008, Proceedings of the National Academy of Sciences.

[16]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[17]  R. Noelle,et al.  Retinoic Acid in the Immune System , 2008, Annals of the New York Academy of Sciences.

[18]  Wen-Hui Lee,et al.  All-trans Retinoic Acid Inhibits Type 1 Diabetes by T Regulatory (Treg)-Dependent Suppression of Interferon-γ–Producing T-cells Without Affecting Th17 Cells , 2008, Diabetes.

[19]  Xiaomin Song,et al.  TGF-β and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3 , 2008, Proceedings of the National Academy of Sciences.

[20]  Irma Joosten,et al.  Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. , 2008, Blood.

[21]  Erin L. Schenk,et al.  Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo1 , 2008, The Journal of Immunology.

[22]  E. Samy,et al.  The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. , 2008, Journal of autoimmunity.

[23]  W. van Eden,et al.  Oral or Nasal Antigen Induces Regulatory T Cells That Suppress Arthritis and Proliferation of Arthritogenic T Cells in Joint Draining Lymph Nodes , 2008, The Journal of Immunology.

[24]  A. Ho,et al.  Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[25]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[26]  L. Boon,et al.  Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. , 2008, Blood.

[27]  Yuka Kanno,et al.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. , 2008, Blood.

[28]  Min-jung Park,et al.  Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model , 2008, Arthritis research & therapy.

[29]  B. Prakken,et al.  Regulatory T cells in autologous stem cell transplantation for autoimmune disease , 2008, Autoimmunity.

[30]  S. Keshav.  Faculty Opinions recommendation of Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. , 2007 .

[31]  E. Olson,et al.  Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.

[32]  P. Smolewski,et al.  Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis , 2007, Annals of the rheumatic diseases.

[33]  H. Broxmeyer,et al.  Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[34]  M. Lazar,et al.  Activation of retinoic acid receptor‐α favours regulatory T cell induction at the expense of IL‐17‐secreting T helper cell differentiation , 2007, European journal of immunology.

[35]  R. Noelle,et al.  All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation , 2007, The Journal of experimental medicine.

[36]  E. Shevach,et al.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.

[37]  Hilde Cheroutre,et al.  Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid , 2007, Science.

[38]  W. Strober,et al.  Cutting Edge: Regulatory T Cells Induce CD4+CD25−Foxp3− T Cells or Are Self-Induced to Become Th17 Cells in the Absence of Exogenous TGF-β , 2007, The Journal of Immunology.

[39]  A. Sette,et al.  Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[40]  M. Roncarolo,et al.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. , 2007, International immunology.

[41]  V. Kuchroo,et al.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation , 2007, Nature Medicine.

[42]  Yuan Shen,et al.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression , 2007, Proceedings of the National Academy of Sciences.

[43]  J. Bijlsma,et al.  Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[44]  Mario Delgado,et al.  Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. , 2007, Arthritis and rheumatism.

[45]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[46]  S. Albani,et al.  Modulation of T Cell Function by Combination of Epitope Specific and Low Dose Anticytokine Therapy Controls Autoimmune Arthritis , 2006, PloS one.

[47]  R. Andreesen,et al.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. , 2006, Blood.

[48]  M. Battaglia,et al.  Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.

[49]  E. Hoppenreijs,et al.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study , 2006, Annals of the rheumatic diseases.

[50]  A. Banham.  Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. , 2006, Trends in immunology.

[51]  P. Emery,et al.  Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. , 2006, Rheumatology.

[52]  J. V. van Laar,et al.  Adult stem cells in the treatment of autoimmune diseases. , 2006, Rheumatology.

[53]  J. Bluestone,et al.  Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells1 , 2006, The Journal of Immunology.

[54]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[55]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[56]  A. Chorny,et al.  Vasoactive Intestinal Peptide Generates CD4+CD25+ Regulatory T Cells in vivo , 2006, Annals of the New York Academy of Sciences.

[57]  K. Kinoshita,et al.  Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. , 2006, Clinical immunology.

[58]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[59]  A. Chorny,et al.  Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. , 2006, Blood.

[60]  A. Chorny,et al.  Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[61]  N. Wulffraat,et al.  Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. , 2006, Blood.

[62]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[63]  E. González-Rey,et al.  The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells1 , 2005, The Journal of Immunology.

[64]  A. Chorny,et al.  Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo , 2005, Journal of leukocyte biology.

[65]  David Pozo,et al.  Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Stadelmann,et al.  Tolerance induction by bone marrow transplantation in a multiple sclerosis model. , 2005, Blood.

[67]  A. Sette,et al.  Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis , 2005, The Lancet.

[68]  R. Toes,et al.  Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. , 2005, Arthritis and rheumatism.

[69]  C. Martínez,et al.  Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis , 2005, Arthritis research & therapy.

[70]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[71]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[72]  F. Sallusto,et al.  Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia , 2005, The Journal of experimental medicine.

[73]  P. Isomäki,et al.  CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis , 2005, Clinical and experimental immunology.

[74]  J. Bluestone.  Regulatory T-cell therapy: is it ready for the clinic? , 2005, Nature Reviews Immunology.

[75]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[76]  B. Prakken,et al.  Heat-shock proteins induce T-cell regulation of chronic inflammation , 2005, Nature Reviews Immunology.

[77]  P. Petrow,et al.  The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells , 2005, Arthritis research & therapy.

[78]  N. Wulffraat,et al.  Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity , 2004, Annals of the rheumatic diseases.

[79]  J. Bijlsma,et al.  CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. , 2004, Arthritis and rheumatism.

[80]  D. Isenberg,et al.  Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy , 2004, The Journal of experimental medicine.

[81]  R. Andreesen,et al.  Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells , 2004, Cancer Cell International.

[82]  L. Klareskog,et al.  CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease , 2004, Arthritis research & therapy.

[83]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[84]  H. von Boehmer,et al.  In Vivo Instruction of Suppressor Commitment in Naive T Cells , 2004, The Journal of experimental medicine.

[85]  W. Kuis,et al.  CD4+CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis , 2004, The Journal of Immunology.

[86]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[87]  C. Berry,et al.  Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Kyung-Su Park,et al.  Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen , 2004, Arthritis research & therapy.

[89]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[90]  J. Bluestone,et al.  TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes , 2003, Nature Medicine.

[91]  S. Kamphuis,et al.  The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. , 2003, Arthritis and rheumatism.

[92]  R. Offringa,et al.  CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. , 2003, Arthritis and rheumatism.

[93]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[94]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[95]  L. Chatenoud.  CD3-specific antibody-induced active tolerance: from bench to bedside , 2003, Nature reviews. Immunology.

[96]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[97]  S. Hori,et al.  Supporting Online Material , 2002 .

[98]  J. Killestein.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[99]  J. Bluestone,et al.  Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. , 2002, The Journal of rheumatology.

[100]  H. Weiner,et al.  Activation of CD25+CD4+ Regulatory T Cells by Oral Antigen Administration1 , 2001, The Journal of Immunology.

[101]  G. Kingsley,et al.  Control of rheumatoid arthritis by oral tolerance. , 2001, Arthritis and rheumatism.

[102]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[103]  J. Thompson,et al.  Juvenile arthritis and autoimmunity to type II collagen. , 2001, Arthritis and rheumatism.

[104]  S. Yamagiwa,et al.  A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood1 , 2001, The Journal of Immunology.

[105]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[106]  Mario Delgado,et al.  Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease , 2001, Nature Medicine.

[107]  W. van Eden,et al.  Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. , 2000, Arthritis and rheumatism.

[108]  Mahavir Singh,et al.  A Conserved Mycobacterial Heat Shock Protein (hsp) 70 Sequence Prevents Adjuvant Arthritis upon Nasal Administration and Induces IL-10-Producing T Cells That Cross-React with the Mammalian Self-hsp70 Homologue1 , 2000, The Journal of Immunology.

[109]  H. Weiner,et al.  Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. , 1999, Journal of autoimmunity.

[110]  S. Kaufmann,et al.  Immune response against heat shock proteins in infectious diseases. , 1999, Immunobiology.

[111]  H. Makino,et al.  Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[112]  G. Steiner,et al.  Cytokine production by synovial T cells in rheumatoid arthritis. , 1999, Rheumatology.

[113]  J. Kremer,et al.  Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. , 1998, Arthritis and rheumatism.

[114]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[115]  W. van Eden,et al.  Experimental immunization with anti‐rheumatic bacterial extract OM‐89 induces T cell responses to heat shock protein (hsp)60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA) , 1997, Clinical and experimental immunology.

[116]  W. Kuis,et al.  Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[117]  L. Chatenoud,et al.  CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. , 1997, Journal of immunology.

[118]  O. Kohashi,et al.  Suppression of adjuvant arthritis in rats by induction of oral tolerance to mycobacterial 65‐kDa heat shock protein , 1996, European journal of immunology.

[119]  D. Trentham,et al.  A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[120]  R. Holmdahl,et al.  Mucosal tolerance and suppression of collagen‐induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184‐198 of bovine type II collagen (CII) expressing a dominant T cell epitope , 1996, Clinical and experimental immunology.

[121]  H. Luthra,et al.  Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. , 1995, Journal of immunology.

[122]  G. Rook,et al.  Presence of hsp65 in bacterial extracts (OM-89): A possible mediator of orally-induced tolerance? , 1995, Experientia.

[123]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[124]  H. Weiner,et al.  Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. , 1995, Arthritis and rheumatism.

[125]  W. Ollier,et al.  Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis , 1995, Nature Medicine.

[126]  P. Helders,et al.  Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favorable course of arthritis. , 1995, The Journal of clinical investigation.

[127]  H. Weiner,et al.  Effects of oral administration of type II collagen on rheumatoid arthritis. , 1993, Science.

[128]  E. Sercarz,et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen , 1992, Nature.

[129]  W. van Eden,et al.  Two monoclonal antibodies generated against human hsp60 show reactivity with synovial membranes of patients with juvenile chronic arthritis , 1992, The Journal of experimental medicine.

[130]  M. Rosenthal,et al.  Longterm treatment of rheumatoid arthritis with OM-8980. A retrospective study. , 1991, The Journal of rheumatology.

[131]  H. Weiner,et al.  Antigen-driven bystander suppression after oral administration of antigens , 1991, The Journal of experimental medicine.

[132]  H. Weiner,et al.  Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. , 1990, Journal of immunology.

[133]  T. Vischer.  Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis , 1990, Clinical Rheumatology.

[134]  R. Young,et al.  T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. , 1989, Journal of immunology.

[135]  G. Thorbecke,et al.  Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[136]  K. Asadullah,et al.  Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. , 2009, Cellular immunology.

[137]  V. Strand,et al.  Biologic therapies in rheumatology: lessons learned, future directions , 2007, Nature Reviews Drug Discovery.

[138]  A. Chorny,et al.  Vasoactive intestinal peptide generates CD4CD25 regulatory T cells in vivo , 2005 .

[139]  J. Casanova,et al.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.

[140]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.

[141]  N. Mitchison,et al.  Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. , 1996, Arthritis and rheumatism.

[142]  I. Cohen.  Autoimmunity to chaperonins in the pathogenesis of arthritis and diabetes. , 1991, Annual review of immunology.